Syndromes Investigation trial demonstrated that fondaparinux is non-inferior to enoxaparin in reducing the risk of ischemic events at nine days, but substantially reducing major bleeding and improving long term mortality and morbidity 1 .
• For Thailand, enoxaparin has been the anticoagulant of choice in the acute coronary syndrome (ACS) setting.
• Critical appraisal is necessarily important to justify adopting this new treatment in the era of limited healthcare resources
• A two-part decision-analytic model, comprising a one-year decision tree and a long-term Markov model, was constructed to estimate lifetime costs and quality-adjusted life years (QALYs) from both societal and provider perspectives.
• A one-year decision tree was used because the reduction of major bleeding from fondaparinux occurred rapidly after treatment based on the OASIS-5 trial.
• Markov model was used for year two and onwards under the assumption of no remaining treatment effect. The long term clinical effectiveness was estimated conditional on individual health states occurred during the first year
• Fondaparinux had lower costs while gained more QALYs than enoxaparin in both perspectives indicating that fondaparinux was a cost saving strategy.
• To evaluate long term cost-effectiveness of fondaparinux versus enoxaparin in non-ST elevation acute coronary syndrome (NSTE-ACS) patients in Thailand 
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References
•Dose of fondaparinux was 2.5 mg OD; enoxaparin was 1 mg/kg BID; treatment lasted for 6 days.
•Cost data were based on the studies using Thai database.
•Effectiveness data were derived from OASIS-5 trial while bleeding rates were derived from the Thai Acute Coronary Syndrome Registry (TACSR), the largest ACS cohort study ever conducted in Thailand.
•All costs and outcomes were discounted at the rate of 3%.
•Incremental cost-effectiveness ratios (ICERs) were presented in year 2013 values.
•A series of sensitivity analyses were performed to assess robustness of the constructed model •Of those 22 varied variables in one-way sensitivity analysis, cost of revascularization with major bleeding had great impact on cost saving in both provider and societal perspectives. • The result of probabilistic sensitivity analysis (PSA) showed that at a threshold of 160,000 THB 9 (4,857.3 USD) in Thailand per QALY, fondaparinux had about 99% being cost-effective compared with enoxaparin in both provider and societal perspectives.
• Fondaparinux should be considered as a cost-effective alternative in the treatment of NSTE-ACS compared to enoxaparin based on Thailand's context, especially in the era of limited healthcare resources.
